Cochrane · systematic review · CD013165
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
Natale, P, Palmer, SC, Ruospo, M, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
9
No studies
9
Included studies
NR
No studies 9 · 50%Ungraded 0 · 0%Very low 4 · 22.2%Low 5 · 27.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Potassium binder versus placebo for chronic hyperkalaemia in people with chronic kidney disease (CKD)
Population: people with CKD (including haemodialysis)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (any cause) Potassium binder vs placebo | RR 0.69 [0.11, 4.32] | 4 studies · 688 participants | Very low Downgraded: risk of bias |
Cardiovascular death (newer agents) Potassium binder vs placebo | RR 3.06 [0.13, 74.24] | 1 study · 196 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Cardiac arrhythmia Potassium binder vs placebo | no estimate extracted | NR | No studies |
HRQoL Potassium binder vs placebo | no estimate extracted | 1 study · 289 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serum potassium Potassium binder vs placebo | no estimate extracted | 3 studies · 277 participants | Low Downgraded: risk of bias |
Constipation Potassium binder vs placebo | RR 1.58 [0.71, 3.52] | 4 studies · 425 participants | Very low Downgraded: risk of bias |
Calcium polystyrene sulphonate (CPS) versus sodium polystyrene sulphonate (SPS) for chronic hyperkalaemia in people with chronic kidney disease (CKD)
Population: people with CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (any cause) Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) | no estimate extracted | NR | No studies |
Cardiovascular death Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) | no estimate extracted | NR | No studies |
Cardiac arrhythmia Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) | no estimate extracted | NR | No studies |
HRQoL Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) | no estimate extracted | NR | No studies |
Serum potassium Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) | no estimate extracted | 2 studies · 117 participants | Low Downgraded: risk of bias |
Constipation Calcium polystyrene sulphonate (CPS) vs sodium polystyrene sulphonate (SPS) | RR 0.7 [0.26, 1.88] | 1 study · 97 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
High versus with low‐dose potassium binder for chronic hyperkalaemia in people with chronic kidney disease (CKD)
Population: people with CKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (any cause; sudden death) High vs with low‐dose potassium binder | RR 1.94 [0.18, 21.08] | 1 study · 203 participants | Low Downgraded: imprecision |
Cardiovascular death High vs with low‐dose potassium binder | no estimate extracted | NR | No studies |
Cardiac arrhythmia High vs with low‐dose potassium binder | no estimate extracted | NR | No studies |
HRQoL High vs with low‐dose potassium binder | no estimate extracted | NR | No studies |
Serum potassium High vs with low‐dose potassium binder | no estimate extracted | NR | No studies |
Constipation High vs with low‐dose potassium binder | RR 1.46 [0.54, 3.94] | 1 study · 203 participants | Low Downgraded: imprecision |